Gary Gordon
Impact in
-
- Hormonal and reproductive studies
- Hormonal Regulation and Hypertension
- Oncology top 2%
- PARP inhibition in cancer therapy
Papers in
- Oncology 32
- Cancer Treatment and Pharmacology 14
- Co-authors
- D. FournierYuesheng ZhangStephen P. SpielbergHarlan F. WeismanDavid A. BlakeLisa M. ShantzPaul TalalayDavid E. Bush
- Journals
- Journal of Clinical Oncology (16 papers)Clinical Cancer Research (5 papers)Annals of Oncology (5 papers)Cancer Research (3 papers)JNCI Journal of the National Cancer Institute (2 papers)
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Gary Gordon
101 papers receiving 4.3k citations
Peers
Comparison fields: 5 of 146
- Endocrinology, Diabetes and Metabolism 705
- Oncology 1.0k
- Pharmacology 623
- Pharmacology 294
- Cancer Research 484
Countries citing papers authored by Gary Gordon
This map shows the geographic impact of Gary Gordon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Gordon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Gordon more than expected).
Fields of papers citing papers by Gary Gordon
This network shows the impact of papers produced by Gary Gordon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Gordon. The network helps show where Gary Gordon may publish in the future.
Co-authors
The 25 scholars most cited alongside Gary Gordon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 2 | |
| 5 | 2023 | 2 | |
| 6 | 2021 | 6 | |
| 7 | 2020 | 17 | |
| 8 | 2016 | 0 | |
| 9 | 2011 | 36 | |
| 10 | 2010 | 167 | |
| 11 | Abstract #5456: Correlation between inhibition of the activity of poly(ADP-ribose) polymerase (PARP) in human peripheral blood mononuclear cells (PBMCs) and tumor biopsies following treatment with ABT-888, an inhibitor of PARP | 2009 | 6 |
| 12 | 2008 | 78 | |
| 13 | 2007 | 31 | |
| 14 | 2003 | 29 | |
| 15 | 1991 | 131 | |
| 16 | 1991 | 25 | |
| 17 | 1990 | 29 | |
| 18 | 1989 | 10 | |
| 19 | 1989 | 14 | |
| 20 | 1988 | 203 |
About Gary Gordon
Gary Gordon is a scholar working on Oncology, Cancer Research, Endocrinology, Diabetes and Metabolism, Pharmacology and Discrete Mathematics and Combinatorics, having authored 105 papers that have together received 4.4k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (14 papers), Hormonal and reproductive studies (10 papers), Lung Cancer Treatments and Mutations (8 papers), Hormonal Regulation and Hypertension (7 papers), Inflammatory mediators and NSAID effects (7 papers), Estrogen and related hormone effects (6 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers) and Pharmacogenetics and Drug Metabolism (5 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (705 citations), Oncology (1.0k citations), Pharmacology (623 citations), Pharmacology (294 citations) and Cancer Research (484 citations). Gary Gordon has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include D. Fournier, Yuesheng Zhang, Stephen P. Spielberg, Harlan F. Weisman, David A. Blake, Lisa M. Shantz, Paul Talalay, David E. Bush, Gary J. Kelloff and Claudio J. Conti. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Annals of Oncology, Cancer Research and JNCI Journal of the National Cancer Institute.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.